PAI
TGTX icon

Pittenger & Anderson Inc’s TG Therapeutics TGTX Stock Holding History

Pittenger & Anderson Inc’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.6K Hold
612
– – ﹤0.01% 340
2026
Q1 		$20.3K Hold
612
– – ﹤0.01% 363
2025
Q4 		$18.2K Hold
612
– – ﹤0.01% 371
2025
Q3 		$22.1K Buy
+612
New +$20.2K ﹤0.01% 338

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pittenger & Anderson Inc's TGTX Position: Q2 2026 in Review

Pittenger & Anderson Inc held its TG Therapeutics (TGTX) position steady in Q2 2026 at 612 shares worth $33.6K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

Pittenger & Anderson Inc first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Pittenger & Anderson Inc held 612 shares of TG Therapeutics worth $33.6K as of Q2 2026.
  • Pittenger & Anderson Inc left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Pittenger & Anderson Inc's portfolio in Q2 2026, its #340 holding.
  • Pittenger & Anderson Inc first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Pittenger & Anderson Inc's 13F filing for Q2 2026, filed 27 Jul 2026.